大園 芳範 (オオゾノ ヨシノリ)

OZONO Yoshinori

写真a

所属

医学部 附属病院 消化器内科

職名

助教

外部リンク

学位 【 表示 / 非表示

  • 博士(医学) ( 2021年3月   宮崎大学 )

 

論文 【 表示 / 非表示

  • Neoplastic fibrocytes play an essential role in bone marrow fibrosis in Jak2V617F-induced primary myelofibrosis mice 査読あり 国際誌

    Ozono Y., Shide K., Kameda T., Kamiunten A., Tahira Y., Sekine M., Akizuki K., Nakamura K., Iwakiri H., Sueta M., Hidaka T., Kubuki Y., Yamamoto S., Hasuike S., Sawaguchi A., Nagata K., Shimoda K.

    Leukemia   35 ( 2 )   454 - 467   2021年2月

     詳細を見る

    担当区分:筆頭著者   記述言語:日本語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Leukemia  

    Primary myelofibrosis (PMF) is a myeloproliferative neoplasm (MPN) characterized by clonal myeloproliferation, progressive bone marrow (BM) fibrosis, splenomegaly, and anemia. BM fibrosis was previously thought to be a reactive phenomenon induced by mesenchymal stromal cells that are stimulated by the overproduction of cytokines such as transforming growth factor (TGF)-β1. However, the involvement of neoplastic fibrocytes in BM fibrosis was recently reported. In this study, we showed that the vast majority of collagen- and fibronectin-producing cells in the BM and spleens of Jak2V617F-induced myelofibrosis (MF) mice were fibrocytes derived from neoplastic hematopoietic cells. Neoplastic monocyte depletion eliminated collagen- and fibronectin-producing fibrocytes in BM and spleen, and ameliorated most characteristic MF features in Jak2V617F transgenic mice, including BM fibrosis, anemia, and splenomegaly, while had little effect on the elevated numbers of megakaryocytes and stem cells in BM, and leukothrombocytosis in peripheral blood. TGF-β1, which was produced by hematopoietic cells including fibrocytes, promoted the differentiation of neoplastic monocytes to fibrocytes, and elevated plasma TGF-β1 levels were normalized by monocyte depletion. Collectively, our data suggest that neoplastic fibrocytes are the major contributor to BM fibrosis in PMF, and TGF-β1 is required for their differentiation.

    DOI: 10.1038/s41375-020-0880-3

    Scopus

    PubMed

    researchmap

  • Efficacy and safety of sofosbuvir and ledipasvir in Japanese patients aged 75 years or over with hepatitis C genotype 1 査読あり

    Ozono Y., Nagata K., Hasuike S., Iwakiri H., Nakamura K., Tsuchimochi M., Yamada Y., Takaishi Y., Sueta M., Miike T., Tahara Y., Yamamoto S., Shide K., Hidaka T., Kubuki Y., Kusumoto K., Ochiai T., Kato J., Komada N., Hirono S., Kuroki K., Shigehira M., Shimoda K.

    World Journal of Hepatology   9 ( 36 )   1340 - 1345   2017年12月

     詳細を見る

    担当区分:筆頭著者   記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:World Journal of Hepatology  

    AIM To evaluate the efficacy and safety of a regimen containing sofosbuvir (SOF) and ledipasvir (LDV) in Japanese patients aged ≥ 75 years with hepatitis C genotype 1. METHODS This multicenter, retrospective study consisted of 246 Japanese patients with HCV genotype 1 at nine centers in Miyazaki prefecture in Japan. Demographic, clinical, virological, and adverse effects (AE)-related data obtained during and after SOF/LDV therapy were collected from medical records. These patients were divided into two groups, younger (aged < 75 years) and elderly (aged ≥ 75 years). Virological data and AEs were analyzed by age group. RESULTS The sustained virological response (SVR) rates at 12 wk after treatment were 99.2%, 99.4%, and 98.7% in the overall population and in patients aged < 75 and ≥ 75 years, respectively. Common AEs during therapy were headache, pruritus, constipation, and insomnia. These occurred in fewer than 10% of patients, and their incidence was not significantly different between the younger and elderly groups. Two patients discontinued treatment, one due to a skin eruption and the other due to cerebral bleeding. CONCLUSION Compared with younger patients, elderly patients had a similar virological response and tolerance to SOF/LDV therapy.

    DOI: 10.4254/wjh.v9.i36.1340

    Scopus

    PubMed

  • Liver abscess in advanced hepatocellular carcinoma after atezolizumab plus bevacizumab treatment: A case report. 査読あり

    Uchida K, Ozono Y, Uchiyama N, Hatada H, Nakamura K, Komaki Y, Iwakiri H, Hasuike S, Nagata K, Sato Y, Kawakami H

    Medicine   101 ( 35 )   e30486   2022年9月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1097/MD.0000000000030486

    PubMed

  • 特集 胆道ドレナージのすべて-適応・方法 2.各論(7)経皮的胆囊ドレナージ

    河上 洋, 畑田 紘志, 内山 尚美, 小川 宗一郎, 田村 穂高, 大園 芳範

    臨床消化器内科   37 ( 10 )   1342 - 1349   2022年8月

     詳細を見る

    掲載種別:研究論文(学術雑誌)   出版者・発行元:日本メディカルセンター  

    DOI: 10.19020/cg.0000002361

    CiNii Research

  • Hematochezia Due to Panitumumab-induced Colitis with Vitamin K Deficiency. 査読あり

    Tamura H, Nakashima K, Uchiyama N, Ogawa S, Hatada H, Yoshida N, Uchida K, Ozono Y, Tanaka H, Yamamto K, Kawakami H

    Internal medicine (Tokyo, Japan)   61 ( 10 )   1503 - 1509   2022年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:一般社団法人 日本内科学会  

    Panitumumab, a fully human anti-epidermal growth factor receptor (EGFR) monoclonal antibody, has been shown to be useful in treating either advanced or recurrent KRAS/NRAS/BRAF wild-type colorectal cancer. We herein report the case of a 60-year-old man with short bowel syndrome who developed hematochezia due to panitumumab-induced colitis with vitamin K deficiency during third-line chemotherapy. The cause of vitamin K deficiency was the lack of intravenous vitamin K supplementation following a change from central venous nutrition to peripheral venous nutrition. We advise clinicians to carefully check for colitis and manage the infusions of chemotherapy patients with short bowel syndrome.

    DOI: 10.2169/internalmedicine.8254-21

    PubMed

    CiNii Research

    researchmap

全件表示 >>

科研費(文科省・学振・厚労省)獲得実績 【 表示 / 非表示

  • 肝硬変、NASH発症・進展に果たす造血細胞の関与の解明と新たな治療標的の確立

    研究課題/領域番号:19K17404  2019年04月 - 2022年03月

    科学研究費補助金  若手研究

     詳細を見る

    担当区分:研究代表者 

寄附金・講座・研究部門 【 表示 / 非表示

  • 消化器内科学講座研究奨学金

    寄附者名称:協和キリン株式会社 2022年10月